CDK9 Protein

CDK9 Protein (Cyclin-Dependent Kinase 9)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CDK9 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>CDK9 (Cyclin-Dependent Kinase 9)</td></tr>
<tr><td><strong>Gene</strong></td><td>[CDK9](/genes/cdk9)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P50750" target="_blank">P50750</a></td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~43 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>CDK family, P-TEFb complex</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>

Overview

CDK9 (Cyclin-Dependent Kinase 9) is a serine/threonine kinase that forms the catalytic core of the positive transcription elongation factor b (P-TEFb) complex. Together with cyclin T1 (CCNT1) or cyclin T2, CDK9 regulates transcriptional elongation by phosphorylating RNA polymerase II and negative elongation factors[@peterlin2015].

CDK9 Protein (Cyclin-Dependent Kinase 9)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CDK9 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>CDK9 (Cyclin-Dependent Kinase 9)</td></tr>
<tr><td><strong>Gene</strong></td><td>[CDK9](/genes/cdk9)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P50750" target="_blank">P50750</a></td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~43 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>CDK family, P-TEFb complex</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>

Overview

CDK9 (Cyclin-Dependent Kinase 9) is a serine/threonine kinase that forms the catalytic core of the positive transcription elongation factor b (P-TEFb) complex. Together with cyclin T1 (CCNT1) or cyclin T2, CDK9 regulates transcriptional elongation by phosphorylating RNA polymerase II and negative elongation factors[@peterlin2015].

CDK9 has emerged as an important player in neurodegenerative diseases through its regulation of genes involved in neuronal survival, protein homeostasis, and stress responses. Its activity is dysregulated in Alzheimer's disease and other tauopathies[@liu2022].

Structure and Function

CDK9 is a 372-amino acid protein kinase that shares structural features with other CDKs but has distinct regulatory properties. The kinase domain is located in the C-terminal portion, while the N-terminal region mediates interactions with cyclins and regulatory proteins[@baumann2019].

The P-TEFb complex (CDK9-cyclin T) is the major regulator of transcription elongation in eukaryotes. CDK9 phosphorylates Ser2 of the RNA Pol II CTD, which promotes transition from initiation to productive elongation. Additionally, CDK9 phosphorylates and inactivates negative elongation factors NELF and DSIF, releasing paused RNA Pol II[@zhou2020].

Role in Neurodegeneration

Alzheimer's Disease

CDK9 activity is altered in Alzheimer's disease, with studies showing both increased and decreased activity depending on disease stage and brain region. CDK9-mediated phosphorylation of tau at certain sites may influence tau pathology, while its role in regulating transcription of stress response genes could affect neuronal survival[@zhang2021].

The connection between CDK9 and tau is particularly relevant. CDK9 can phosphorylate tau at multiple sites, potentially influencing its aggregation propensity and clearance. Pharmacological inhibition of CDK9 has shown neuroprotective effects in some AD models[@wang2020].

Parkinson's Disease

In Parkinson's disease, CDK9 may protect dopaminergic [neurons](/entities/neurons) through its regulation of genes involved in mitochondrial function and protein quality control. CDK9 inhibition can sensitize neurons to mitochondrial toxins, while enhanced CDK9 activity may provide neuroprotection[@kim2022].

Huntington's Disease

CDK9 has been implicated in Huntington's disease through its regulation of mutant [huntingtin](/proteins/huntingtin) expression and neuronal stress responses. CDK9 inhibitors are being explored as potential therapeutics, though concerns about transcriptional side effects remain[@tay2021].

Therapeutic Implications

CDK9 inhibitors have been developed for cancer therapy but may have applications in neurodegenerative diseases. The challenge lies in achieving neuroprotective effects without causing unacceptable transcriptional suppression. Selective modulation of specific CDK9 functions or cell-type-specific delivery are potential strategies[@huang2023].

Key Findings

• CDK9 is the catalytic subunit of P-TEFb, regulating transcription elongation[@peterlin2015]
• CDK9 activity is dysregulated in AD and PD brain tissue[@liu2022]
• CDK9 can phosphorylate [tau protein](/proteins/tau)[@baumann2019]
• CDK9 inhibition provides neuroprotection in some models[@zhou2020]
• CDK9-targeted therapies require careful optimization[@zhang2021]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References